scholarly journals SGLT2 inhibitors and renal complications in type 1 diabetes

2020 ◽  
Vol 8 (10) ◽  
pp. 803-805
Author(s):  
John R Petrie
Keyword(s):  
Type 1 Diabetes ◽  
Sglt2 Inhibitors ◽  
Renal Complications

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice

2020 ◽  
Vol 22 (3) ◽  
pp. 208-215 ◽  
Author(s):  
Ane Bayona Cebada ◽  
Lía Nattero-Chávez ◽  
Sara Alonso Díaz ◽  
Héctor F. Escobar-Morreale ◽  
Manuel Luque-Ramírez
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Sglt2 Inhibitors ◽  
Efficacy And Safety ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
David S. H. Bell
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Case Reports ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Endogenous Insulin ◽  
Large Randomized Clinical Trial ◽  
Endogenous Insulin Production

SGLT2 inhibitors are only approved for use in adults with type 2 diabetes. However, because SGLT2 inhibitors have a mechanism of action that does not require the presence of endogenous insulin, these drugs should also be efficacious in type 1 diabetes where endogenous insulin production is greatly reduced or absent. Herein, I present five cases which illustrate the benefits of utilizing an SGLT2 inhibitor with type 1 diabetes. In these cases the use of SGLT2 inhibitors resulted not only in better glycemic control in most patients but also in some patients’ less hypoglycemia, weight loss, and decreased doses of insulin. In type 1 diabetesCandida albicansvaginitis and balanitis may occur more frequently than in type 2 diabetes. These cases show that a large randomized clinical trial of SGLT2 inhibitors in type 1 diabetes needs to be performed.

scholarly journals Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes

2016 ◽  
Vol 10 (5) ◽  
pp. 1006-1014 ◽  
Author(s):  
Elsa Ahlén ◽  
Aldina Pivodic ◽  
Hans Wedel ◽  
Sofia Dahlqvist ◽  
Mikhail Kosiborod ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Excess Risk ◽  
Current Smoking ◽  
Renal Complications ◽  
Risk Of Mortality

1124-P: SGLT2 Inhibitors as Adjuvant Therapy for Type 1 Diabetes: An Italian Center Experience

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1124-P
Author(s):  
SILVIA PIERALICE ◽  
DARIO TUCCINARDI ◽  
SHADI KYANVASH ◽  
DARIA MAGGI ◽  
LAVINIA MONTE ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Adjuvant Therapy ◽  
Sglt2 Inhibitors

scholarly journals Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes

2019 ◽  
Vol 11 (1) ◽  
pp. 37-52 ◽  
Author(s):  
Marc Evans ◽  
Debbie Hicks ◽  
Dipesh Patel ◽  
Vinod Patel ◽  
Phil McEwan ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sglt2 Inhibitors

1145-P: SGLT2 Inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1145-P
Author(s):  
KOKI CHIBA ◽  
KYUYONG CHO ◽  
HIRAKU KAMEDA ◽  
AKINOBU NAKAMURA ◽  
YUI SHIBAYAMA ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glucose Variability ◽  
Sglt2 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document